CytoDyn

293 articles with CytoDyn

• CytoDyn to Present Findings on Its Feline Immunodeficiency Virus (FIV) Therapeutic Antibody Program

  10/5/2012

• CytoDyn Retains Gibraltar Associates for Corporate and Investor Communications

  10/3/2012

• CytoDyn Names Dr. Nader Pourhassan New CEO

  9/12/2012

• CytoDyn Announces Management Update Conference Call on Thursday, August 23

  8/22/2012

• CytoDyn Announces Entry into Agreement With Progenics Pharmaceuticals, Inc. to Acquire PRO 140

  7/31/2012

• CytoDyn Announces Plans to Move Forward With Next Stage of Research of CytoFeline™

  5/17/2012

• CytoDyn Engages the Trout Group for Investor Relations Services

  4/16/2012

• CytoDyn Presenting at The Wall Street Forum's 23rd Annual Analyst Conference in New York, New York

  4/4/2012

• Ismail Abdul Fattah Agrees to Become CytoDyn's Senior Advisor of Business Development for the Middle East

  1/19/2012

• CytoDyn Presenting Update on its Therapeutic Antibody Programs at the Therapeutic Potential of Antibodies for HIV Meeting in Boston, MA

  1/17/2012

• CytoDyn Appoints Anthony D. Caracciolo to Serve as a Member of the Board of Directors

  12/21/2011

• CytoDyn Enters into Research Funding and Option Agreement With The Scripps Research Institute

  11/17/2011

• CytoDyn Announces Humanized Cytolin(R) Provisional Patent Application Filed for the Treatment of HIV/AIDS

  9/26/2011

• CytoDyn Announces Consulting Arrangement with SDG, LLC

  9/9/2011

• CytoDyn Announces Provisional FIV Patent Filing

  8/8/2011

• CytoDyn Announces New Role for Nader Pourhassan

  7/6/2011

• CytoDyn Elects New President and CEO

  12/9/2010

• CytoDyn Welcomes Banker Kenneth J. Van Ness to Its Board of Directors

  6/17/2010

• CytoDyn Raises Three Million Dollars in Private Placements

  3/31/2010

• CytoDyn Increases Study Budget to Accelerate Clinical Trial

  3/22/2010